# Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)

> **NCT00000630** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 35 (—)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** HIVAC-1e
- **BIOLOGICAL:** gp160 Vaccine (MicroGeneSys)

## Key facts

- **NCT ID:** NCT00000630
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1992-12
- **Target enrollment:** 35 (—)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000630, "Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00000630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*